Search Results

There are 4243 results for: content related to: Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease

  1. You have free access to this content
    Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression

    International Journal of Cancer

    Volume 130, Issue 12, 15 June 2012, Pages: 2835–2844, Latif A. Wafa, Helen Cheng, Nathan Plaa, Fariba Ghaidi, Takahiro Fukumoto, Ladan Fazli, Martin E. Gleave, Michael E. Cox and Paul S. Rennie

    Version of Record online : 14 SEP 2011, DOI: 10.1002/ijc.26287

  2. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Version of Record online : 19 JUN 2012, DOI: 10.1002/mds.25051

  3. You have free access to this content
    Poster Session

    Movement Disorders

    Volume 31, Issue S2, June 2016, Pages: S1–S697,

    Version of Record online : 19 JUN 2016, DOI: 10.1002/mds.26688

  4. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors

    The Prostate

    Volume 72, Issue 8, 1 June 2012, Pages: 875–885, Christian Thomas, Latif A. Wafa, Francois Lamoureux, Helen Cheng, Ladan Fazli, Martin E. Gleave and Paul S. Rennie

    Version of Record online : 5 OCT 2011, DOI: 10.1002/pros.21490

  5. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 30, Issue S1, June 2015, Pages: S1–S567,

    Version of Record online : 12 JUN 2015, DOI: 10.1002/mds.26295

  6. You have free access to this content
    Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses

    British Journal of Clinical Pharmacology

    Volume 58, Issue s1, November 2004, Pages: 41–49, Chukwuemeka S. Okereke, Louis Kirby, Dinesh Kumar, Edward I. Cullen, Raymond D. Pratt and William A. Hahne

    Version of Record online : 20 OCT 2004, DOI: 10.1111/j.1365-2125.2004.01799.x

  7. Lack of Pharmacokinetic Interactions Between Transdermal Rotigotine and Oral Levodopa/Carbidopa

    The Journal of Clinical Pharmacology

    Volume 49, Issue 9, September 2009, Pages: 1047–1055, Marina Braun, Willi Cawello, Jens-Otto Andreas, Dipl Math, Hilmar Boekens and Rolf Horstmann

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009338481

  8. You have free access to this content
    COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet®)

    British Journal of Clinical Pharmacology

    Volume 48, Issue 3, September 1999, Pages: 449–452, Karin M. Jorga and David J. Nicholl

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.1999.00027.x

  9. Pharmacokinetics of Levodopa/Carbidopa Delivered From Gastric-Retentive Extended-Release Formulations in Patients With Parkinson's Disease

    The Journal of Clinical Pharmacology

    Volume 52, Issue 7, July 2012, Pages: 1069–1077, Cuiping Chen, Verne E. Cowles, Mike Sweeney, Igor D. Stolyarov and Sergey N. Illarioshkin

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011409232

  10. You have free access to this content
    Entacapone improves the availability of l-dopa in plasma by decreasing its peripheral metabolism independent of l-dopa/carbidopa dose

    British Journal of Clinical Pharmacology

    Volume 54, Issue 4, October 2002, Pages: 363–371, Helena Heikkinen, Anu Varhe, Tarmo Laine, Jaakko Puttonen, Marjo Kela, Seppo Kaakkola and Kari Reinikainen

    Version of Record online : 23 OCT 2002, DOI: 10.1046/j.1365-2125.2002.01654.x

  11. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 29, Issue S1, May 2014, Pages: S1–S571,

    Version of Record online : 6 JUN 2014, DOI: 10.1002/mds.25914

  12. You have free access to this content
    Pharmacokinetics of levodopa/benserazide versus levodopa/carbidopa in healthy subjects and patients with Parkinson's disease

    Neurology and Clinical Neuroscience

    Volume 3, Issue 2, March 2015, Pages: 68–73, Hirotaka Iwaki, Noriko Nishikawa, Masahiro Nagai, Tomoaki Tsujii, Hayato Yabe, Madoka Kubo, Ichiro Ieiri and Masahiro Nomoto

    Version of Record online : 8 DEC 2014, DOI: 10.1111/ncn3.152

  13. Development and validation of a high-performance liquid chromatography–electrospray ionization–MS/MS method for the simultaneous quantitation of levodopa and carbidopa in human plasma

    Journal of Mass Spectrometry

    Volume 46, Issue 9, September 2011, Pages: 943–948, Isabela Costa César, Ricardo Martins Duarte Byrro, Fabiana Fernandes de Santana e Silva Cardoso, Iram Moreira Mundim, Leonardo de Souza Teixeira, Sandro Antônio Gomes, Ricardo Rodrigues Bonfim and Gerson Antônio Pianetti

    Version of Record online : 13 SEP 2011, DOI: 10.1002/jms.1973

  14. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

    Movement Disorders

    Volume 26, Issue S3, October 2011, Pages: S2–S41, Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz and Cristina Sampaio

    Version of Record online : 21 OCT 2011, DOI: 10.1002/mds.23829

  15. You have full text access to this OnlineOpen article
    Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets

    British Journal of Clinical Pharmacology

    Volume 78, Issue 1, July 2014, Pages: 94–105, Ahmed A. Othman and Sandeep Dutta

    Version of Record online : 20 JUN 2014, DOI: 10.1111/bcp.12324

  16. Carbidopa/levodopa pharmacy errors in Parkinson's disease

    Movement Disorders

    Volume 25, Issue 16, 15 December 2010, Pages: 2867–2871, Nasim R. Khadem and Melissa J. Nirenberg

    Version of Record online : 3 SEP 2010, DOI: 10.1002/mds.23311

  17. Sensitive determination of carbidopa through the electrochemiluminescence of luminol at graphene-modified electrodes

    Luminescence

    Volume 30, Issue 4, June 2015, Pages: 376–381, Morteza Hosseini, Nooshin Mirzanasiri, Morteza Rezapour, Mohammad Hasan Sheikhha, Farnoush Faridbod, Parviz Norouzi and Mohammad Reza Ganjali

    Version of Record online : 13 AUG 2014, DOI: 10.1002/bio.2742

  18. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naïve primates

    Movement Disorders

    Volume 20, Issue 3, March 2005, Pages: 306–314, Lance A. Smith, Michael J. Jackson, Ghassan Al-Barghouthy, Sarah Rose, Mikko Kuoppamaki, Warren Olanow and Peter Jenner

    Version of Record online : 15 OCT 2004, DOI: 10.1002/mds.20317

  19. Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease

    Movement Disorders

    Volume 17, Issue 5, September/October 2002, Pages: 961–968, Robert A. Hauser and Nicholas H.G. Holford

    Version of Record online : 25 APR 2002, DOI: 10.1002/mds.10226

  20. Improving l-dopa therapy: The development of enzyme inhibitors

    Movement Disorders

    Volume 30, Issue 1, January 2015, Pages: 103–113, Oscar S. Gershanik

    Version of Record online : 21 OCT 2014, DOI: 10.1002/mds.26050